The IntegenX programs focus on developing platforms for DNA sample preparation, sequencing library preparation and sample-to-answer analysis of human genotypes.
IntegenX president and CEO Stevan Jovanovich said that they are pleased to receive federal recognition that their platforms have the potential for impacting the development of therapeutics, molecular diagnostics, and discovery of genetic markers that will improve outcomes for patients.
"These awards provide IntegenX with additional support to continue development of our products and to accelerate advancing them to the market," Jovanovich said.